Skip to main content Skip to footer content

iOS 17 Release

Apple has implemented 2 new features in iOS 17 that will affect your experience with the Eversense CGM System.

StandBy Mode, when enabled, activates the iPhone lock screen when the phone is charging and on its side.  StandBy mode affects the Eversense App’s ability to provide alerts in all the ways you expect.  If StandBy mode is used, be sure you have turned on Show Notifications in Settings > StandBy.  On-body vibe alerts from the transmitter are not impacted.

Assistive Access Mode, when enabled, provides a cognitive accessibility feature that will change the way you access the Eversense app and changes how alerts are presented when the app is not open.  On-body vibe alerts from the transmitter are not impacted, however, this feature may result in brief, intermittent interference with the transmitter’s Bluetooth connection to your phone.  To download, install and create an Eversense Account, Assistive Access Mode must be turned off.  Once the account is created, the Eversense App may be added to Assistive Access Mode.

You should disable automatic updates to your mobile device.  Some operating system updates may result in a need for a supporting update to the Eversense Mobile App.  Once we have verified compatibility of new operating systems with Eversense, our compatibility page will be updated.

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://global.eversensediabetes.com/safety-info.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal procedures are performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.

Senseonics_Logo_White_0